Literature DB >> 30997581

Implementing a central composite design for the optimization of solid phase microextraction to establish the urinary volatomic expression: a first approach for breast cancer.

Catarina L Silva1, Rosa Perestrelo1, Pedro Silva1, Helena Tomás1,2, José S Câmara3,4.   

Abstract

INTRODUCTION: Breast cancer (BC) is positioned as the second among all cancers remaining at the top of women´s diseases worldwide followed by colorectum, lung, cervix, and thyroid cancers. The main drawback of most the screening/diagnostic methods is their low sensitivity/specificity and in some cases the invasive procedure required to obtain the samples.
OBJECTIVES: On the present investigation, we report a statistical design was to evaluate by central composite design the influence towards the optimization of the most significant variables of solid-phase microextraction (SPME) procedure for the isolation of volatile organic metabolites (VOMs) from urine of BC patients (N = 31) and healthy individuals (CTL; N = 40). The establishment of the urinary volatomic composition, through gas chromatography-mass spectrometry (GC-MS) analysis, can boost the identification of volatile organic metabolites (VOMs) potential BC biomarkers useful to be used together or to complement the current BC diagnostics tools. Better early detection methods are needed to improve the outcomes of patients with BC.
METHODS: Several combinations of experiments were considered with a central composite design (CCD) of response surface methodology (RSM) for the urinary volatomic pattern. Three-level three-factor CCD was employed assessing the most important extraction-influencing variables-fiber coating, NaCl amount, extraction time and temperature. The optimal conditions were achieved using a carboxen/polydimethylsiloxane fiber with 15% (w/v) NaCl during 75 min at 50 °C.
RESULTS: A total of ten VOMs belonging to sulfur compounds, terpenoids and carbonyl compounds presented the highest contribution towards discrimination of BC patients from CTL (variable importance in projection (VIP) > 1, p < 0.05). The discrimination efficiency and accuracy of urinary metabolites was ascertained by receiver operating characteristic (ROC) curve analysis that allowed the identification of some metabolites with highest sensitivity and specificity to discriminate the groups.
CONCLUSIONS: The results obtained with this approach suggest the possibility to identify endogenous metabolites as a platform to discovery potential BC biomarkers and paves a way to explore the related metabolomic pathways in order to improve BC diagnostic tools.

Entities:  

Keywords:  Breast cancer; Central composite design; Chemometric tools; Metabolomics; Urine

Mesh:

Substances:

Year:  2019        PMID: 30997581     DOI: 10.1007/s11306-019-1525-2

Source DB:  PubMed          Journal:  Metabolomics        ISSN: 1573-3882            Impact factor:   4.290


  27 in total

Review 1.  Recent and potential developments of biofluid analyses in metabolomics.

Authors:  Aihua Zhang; Hui Sun; Ping Wang; Ying Han; Xijun Wang
Journal:  J Proteomics       Date:  2011-11-04       Impact factor: 4.044

Review 2.  Receiver Operating Characteristic (ROC) Curve Analysis for Medical Diagnostic Test Evaluation.

Authors:  Karimollah Hajian-Tilaki
Journal:  Caspian J Intern Med       Date:  2013

Review 3.  Serum tumor markers in breast cancer: are they of clinical value?

Authors:  Michael J Duffy
Journal:  Clin Chem       Date:  2006-01-12       Impact factor: 8.327

4.  Screening of salivary volatiles for putative breast cancer discrimination: an exploratory study involving geographically distant populations.

Authors:  Carina Cavaco; Jorge A M Pereira; Khushman Taunk; Ravindra Taware; Srikanth Rapole; Hampapathalu Nagarajaram; José S Câmara
Journal:  Anal Bioanal Chem       Date:  2018-05-07       Impact factor: 4.142

5.  Early diagnosis and detection of breast cancer.

Authors:  Marina Milosevic; Dragan Jankovic; Aleksandar Milenkovic; Dragan Stojanov
Journal:  Technol Health Care       Date:  2018       Impact factor: 1.285

6.  Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease.

Authors:  Maitreyi Raman; Iftikhar Ahmed; Patrick M Gillevet; Chris S Probert; Norman M Ratcliffe; Steve Smith; Rosemary Greenwood; Masoumeh Sikaroodi; Victor Lam; Pam Crotty; Jennifer Bailey; Robert P Myers; Kevin P Rioux
Journal:  Clin Gastroenterol Hepatol       Date:  2013-02-27       Impact factor: 11.382

Review 7.  Metabolomics in breast cancer: A decade in review.

Authors:  Amelia McCartney; Alessia Vignoli; Laura Biganzoli; Richard Love; Leonardo Tenori; Claudio Luchinat; Angelo Di Leo
Journal:  Cancer Treat Rev       Date:  2018-05-03       Impact factor: 12.111

8.  Investigation of urinary volatile organic metabolites as potential cancer biomarkers by solid-phase microextraction in combination with gas chromatography-mass spectrometry.

Authors:  C L Silva; M Passos; J S Câmara
Journal:  Br J Cancer       Date:  2011-11-15       Impact factor: 7.640

9.  Volatile metabolomic signature of human breast cancer cell lines.

Authors:  Catarina L Silva; Rosa Perestrelo; Pedro Silva; Helena Tomás; José S Câmara
Journal:  Sci Rep       Date:  2017-03-03       Impact factor: 4.379

10.  Investigation of VOCs associated with different characteristics of breast cancer cells.

Authors:  Luca Lavra; Alexandro Catini; Alessandra Ulivieri; Rosamaria Capuano; Leila Baghernajad Salehi; Salvatore Sciacchitano; Armando Bartolazzi; Sara Nardis; Roberto Paolesse; Eugenio Martinelli; Corrado Di Natale
Journal:  Sci Rep       Date:  2015-08-25       Impact factor: 4.379

View more
  7 in total

1.  Chemometric Analysis of Urinary Volatile Organic Compounds to Monitor the Efficacy of Pitavastatin Treatments on Mammary Tumor Progression over Time.

Authors:  Paul Grocki; Mark Woollam; Luqi Wang; Shengzhi Liu; Maitri Kalra; Amanda P Siegel; Bai-Yan Li; Hiroki Yokota; Mangilal Agarwal
Journal:  Molecules       Date:  2022-07-03       Impact factor: 4.927

2.  Urinary Volatile Organic Compound Testing in Fast-Track Patients with Suspected Colorectal Cancer.

Authors:  Caroline E Boulind; Oliver Gould; Ben de Lacy Costello; Joanna Allison; Paul White; Paul Ewings; Alfian N Wicaksono; Nathan J Curtis; Anne Pullyblank; David Jayne; James A Covington; Norman Ratcliffe; Claire Turner; Nader K Francis
Journal:  Cancers (Basel)       Date:  2022-04-24       Impact factor: 6.575

Review 3.  Volatile Organic Compounds Analysis as a Potential Novel Screening Tool for Breast Cancer: A Systematic Review.

Authors:  Michelle Leemans; Pierre Bauër; Vincent Cuzuel; Etienne Audureau; Isabelle Fromantin
Journal:  Biomark Insights       Date:  2022-05-23

4.  Human Plasma Metabolomics for Biomarker Discovery: Targeting the Molecular Subtypes in Breast Cancer.

Authors:  Leticia Díaz-Beltrán; Carmen González-Olmedo; Natalia Luque-Caro; Caridad Díaz; Ariadna Martín-Blázquez; Mónica Fernández-Navarro; Ana Laura Ortega-Granados; Fernando Gálvez-Montosa; Francisca Vicente; José Pérez Del Palacio; Pedro Sánchez-Rovira
Journal:  Cancers (Basel)       Date:  2021-01-05       Impact factor: 6.639

5.  Discovery of Volatile Biomarkers for Bladder Cancer Detection and Staging through Urine Metabolomics.

Authors:  Joana Pinto; Ângela Carapito; Filipa Amaro; Ana Rita Lima; Carina Carvalho-Maia; Maria Conceição Martins; Carmen Jerónimo; Rui Henrique; Maria de Lourdes Bastos; Paula Guedes de Pinho
Journal:  Metabolites       Date:  2021-03-26

6.  A prediction model using 2-propanol and 2-butanone in urine distinguishes breast cancer.

Authors:  Shoko Kure; Sera Satoi; Toshihiko Kitayama; Yuta Nagase; Nobuo Nakano; Marina Yamada; Noboru Uchiyama; Satoshi Miyashita; Shinya Iida; Hiroyuki Takei; Masao Miyashita
Journal:  Sci Rep       Date:  2021-10-05       Impact factor: 4.379

7.  Evaluation of a Chaotrope and Kosmotrope in the Multivariate Optimization of PHW-ATPE of Solasodine from Leaves of Solanum mauritianum.

Authors:  Tebogo Mphatlalala Mokgehle; Ntakadzeni Edwin Madala; Nikita Tawanda Tavengwa
Journal:  Molecules       Date:  2022-08-29       Impact factor: 4.927

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.